Kupando GmbH
Schönefeld, DE · Founded 2018 · 12 employees on LinkedIn · 3 known investors
Kupando is a biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. Its lead candidate KUP101 combines a TLR4 and a TLR7 agonist in a liposomal formulation for treating solid tumors and preventing infectious diseases.
Founders & leadership
Kupando GmbH was founded in 2018 by Johanna Holldack.
JH
Johanna HolldackCEO
Board
PM
Pierre MorgonChairman
WN
Wolfram NothaftDeputy Chairman
Investors · 3
Frequently asked questions
- What does Kupando GmbH do?
- Kupando is a biopharmaceutical company developing TLR 4/7 agonists that stimulate innate immunity for use in oncology and infectious diseases. Its lead candidate KUP101 combines a TLR4 and a TLR7 agonist in a liposomal formulation for treating solid tumors and preventing infectious diseases.
- Who founded Kupando GmbH?
- Kupando GmbH was founded by Johanna Holldack in 2018.
- Who are Kupando GmbH's investors?
- Kupando GmbH's investors include Brandenburg Kapital, Remiges Ventures, Inc., Ventura BioMed Investors.
- Where is Kupando GmbH headquartered?
- Kupando GmbH is headquartered in Schönefeld, DE.